AC Immune Reports ‘Positive Interim Results’ from Novel Phase 1b/2a Alzheimer’s Vaccine Trial

February 15, 2021

Source: Streetwise Reports   02/11/2021

Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer’s trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer’s disease.

Switzerland-based clinical-stage biopharmaceutical firm AC Immune SA (ACIU:NASDAQ) today announced “positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD).”

The company highlighted that “the ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels.” The firm indicated that there were not any clinically relevant adverse events observed in the study and that the results achieved support its plans to further develop and move the Alzheimer’s vaccine into Phase 2/3.

The company stated that immunization with anti-Tau vaccines is a novel approach in treating AD and other neurodegenerative diseases and claimed that “ACI-35.030 is a first-in-class vaccine candidate designed to generate a specific antibody response against pTau proteins in the brain.”


Get our Weekly Commitment of Traders Reports: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.




Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter






AC Immune’s CEO Professor Andrea Pfeifer stated, “These remarkable data show that ACI-35.030 is capable of generating unprecedented antibody responses against pTau in an elderly population, with very high antigen-specific titers. Importantly, it generated a much stronger antibody response compared to direct injection of exogenous antibodies. As pathological pTau is present as a precursor many years before Tau accumulation in the brain is detectable via brain imaging, such results highlight the significant promise of ACI-35.030 as an early intervention for AD, especially when combined with cutting-edge pTau diagnostics that would enable identification of people at risk of developing Tau-driven disease.”

“We look forward to continuing to advance ACI-35.030 in our collaboration with Janssen Pharmaceuticals Inc., as we aim to bring this potentially breakthrough vaccine to patients,” Pfeifer added.

The firm noted that the interim findings from the Phase 1b/2a trial showed anti-Tau IgG response preferentially targets phosphorylated Tau in all patients with 100% of patients demonstrating an anti-pTau IgG response after the first injection for both lowest and second highest dose amounts.

The firm explained that the Phase 1b/2a pTau AD Vaccine Trial enrolled 32 patients with early AD who were given different doses of ACI-35.030 over 48 weeks. Patients were randomized in the multicenter, double-blind, placebo-controlled clinical study to assess safety, tolerability and immunogenicity of different dosage levels.

The company indicated that it is developing the ACI-35.030 vaccine together in partnership with Janssen Pharmaceuticals and described ACI-35.030 a being “a potent liposomal anti-pTau active investigational vaccine designed to elicit antibodies against phosphorylated pathological Tau protein that is designed to reduce and facilitate the clearance of related Tau aggregates, slowing the progression of Tau-pathology and/or treating the underlying Tauopathy.”

AC Immune is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, that specializes in developing precision medicines for treating neurodegenerative diseases. The firm stated it “utilizes two proprietary discovery platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins.” The company noted that at present its drug pipeline includes nine therapeutic and three diagnostic product candidates, and that six of those are currently being investigated in ongoing clinical trials. The company listed that is now actively collaborating on research projects with several well-known major pharmaceutical companies including Eli Lilly and Co., Janssen Pharmaceuticals and Roche Group’s Genentech.

AC Immune began the day with a market cap of about $524.4 million with around 71.74 million shares outstanding and a short interest of about 1.5%. ACIU shares opened 59% higher today at $11.62 (+$4.31, +58.96%) over yesterday’s $7.31 closing price. The stock has traded today between $7.96 and $12.50 per share and is currently trading at $8.44 (+$1.13, +15.46%).

 

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.